DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-11

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design.

Participants will be:

* screened for the trial via an online platform
* contacted by study personal to obtain electronic consent
* enrolled in the trial if eligible and consented
* contacted by study personal for further instructions and directions
* sent dapagliflozin oral medication (supplied by the site pharmacy)
* followed up regularly with the study team via telemedicine or other online avenues
* monitored using lab work, inquiries about side effects and assessment of protocol adherence at 1 month, 3 months and 6 months
* continue treatment for 6 months

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

NCT06350123

Chronic Kidney Disease

COMPLETED PHASE2

Alirocumab in Patients on a Stable Dialysis Regimen

NCT03480568

Hemodialysis Peritoneal Dialysis Hypercholesterolemia +1 more

UNKNOWN PHASE3

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05510115

Polycystic Kidney, Autosomal Dominant

ACTIVE_NOT_RECRUITING PHASE2

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

NCT04492722

Chronic Kidney Disease

TERMINATED PHASE2

Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency

NCT01223755

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

TERMINATED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Participants are recruited by one of the following methods:

1. Self-referral through the website
2. Receiving recruitment materials from their provider.
2. Participant visits the prescreening website.

1. High level prescreening questions are answered by the participant.
2. If appropriate based on answers to the questions, the participant may provide their contact information for follow up by the study team.
3. Study team contacts potential participants to review the study and explain next steps
4. Participant is provided with the link and password to view the video and sign the consent via Adobe Sign
5. An investigator will meet virtually with the participant to obtain medical history information, concomitant medications, and performance status (screening visit)
6. Once the participant passes screening in step 5, an order will be sent to the participant for the remaining screening labs to be done at a local laboratory that is covered by their insurance
7. The lab will fax results to the site
8. After review of eligibility and the study team will proceed with enrolling the participant if appropriate
9. The participant will proceed to the baseline visit (telehealth for any portion that can be done via phone/video and order for lab tests as previously described) if needed to comply with the protocol calendar/window.
10. The participant is approved to begin dosing by the investigator
11. The site will dispense via mail the following:

1. 4 month's supply of Dapagliflozin
2. A self-addressed envelope for return of the diary and pill bottles at the end of the dosing period
3. A weighing scale (if required)
12. Dosing compliance will be checked during initial study treatment via sharing of pill accountability data or screenshot of paper pill diary
13. If clinically indicated, labs will be ordered and run more frequently to assess for toxicity.
14. Visits 3, 4, and 5 will be conducted in the same manner as described above.
15. All pill bottles and diaries (if paper version is used) will be returned via the provided envelope

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal AL Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dapagliflozin

Dapagliflozin 10mg orally, daily for 6 months

Group Type EXPERIMENTAL

Dapagliflozin

Intervention Type DRUG

10mg orally once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dapagliflozin

10mg orally once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BMS-512148 Forxiga® / Farxiga®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed and dated informed consent form.
* Stated willingness to comply with study procedures, including remote telehealth consultations with the study team, confirming availability, and agreeing to use mobile/web applications for study purposes.
* Age ≥18 years.
* Histopathologic diagnosis of renal AL amyloidosis confirmed by biopsy of any tissue and evidence of \>1.0 g/day proteinuria without any other identifiable cause.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.
* Plateau in any renal response (i.e., reduction in proteinuria) for at least 3 months prior to enrollment, as determined by the enrolling physician.
* Residence in the state of Michigan.

Exclusion Criteria

* Either ongoing first line induction with anti-plasma cell therapy or ongoing post- induction maintenance for \<6 months prior to enrollment.
* Diagnosis of symptomatic multiple myeloma, including presence of lytic bone disease, plasmacytomas, ≥60% plasma cells in the bone marrow, or hypercalcemia, either currently or in the past.
* Women of child-bearing potential (i.e., those who have not undergone chemical or surgical sterilization or are not postmenopausal) and who are unwilling to use a medically accepted and reliable form of contraception while participating in the study and for 2 weeks following the last dose of study medication, as determined by the investigator, or have a positive pregnancy test at the time of enrolment or are currently breastfeeding.
* Known allergic reactions to components of the dapagliflozin.
* Treatment requiring type 1 or type 2 diabetes mellitus.
* Baseline eGFR \<25 mL/min/1.73m2.
* Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices or coagulopathy)
* Current or previous use of any SGLT2i.
* Initiation or dose modification of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) \<3 months prior to enrollment.
* Active malignancy requiring treatment (other than AL amyloidosis and non-melanoma skin cancers).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No